113 related articles for article (PubMed ID: 26867804)
1. Nutlin-3 treatment spares cisplatin-induced inhibition of bone healing while maintaining osteosarcoma toxicity.
Stine KC; Wahl EC; Liu L; Skinner RA; VanderSchilden J; Bunn RC; Montgomery CO; Aronson J; Becton DL; Nicholas RW; Swearingen CJ; Suva LJ; Lumpkin CK
J Orthop Res; 2016 Oct; 34(10):1716-1724. PubMed ID: 26867804
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin inhibits bone healing during distraction osteogenesis.
Stine KC; Wahl EC; Liu L; Skinner RA; Vanderschilden J; Bunn RC; Montgomery CO; Suva LJ; Aronson J; Becton DL; Nicholas RW; Swearingen CJ; Lumpkin CK
J Orthop Res; 2014 Mar; 32(3):464-70. PubMed ID: 24259375
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
4. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models.
Fleuren ED; Versleijen-Jonkers YM; Roeffen MH; Franssen GM; Flucke UE; Houghton PJ; Oyen WJ; Boerman OC; van der Graaf WT
Int J Cancer; 2014 Dec; 135(12):2770-82. PubMed ID: 24771207
[TBL] [Abstract][Full Text] [Related]
5. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
[TBL] [Abstract][Full Text] [Related]
6. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
[TBL] [Abstract][Full Text] [Related]
8. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
de Lange J; Ly LV; Lodder K; Verlaan-de Vries M; Teunisse AF; Jager MJ; Jochemsen AG
Oncogene; 2012 Mar; 31(9):1105-16. PubMed ID: 21765463
[TBL] [Abstract][Full Text] [Related]
9. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
10. MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway.
Zauli G; Rimondi E; Corallini F; Fadda R; Capitani S; Secchiero P
J Bone Miner Res; 2007 Oct; 22(10):1621-30. PubMed ID: 17592964
[TBL] [Abstract][Full Text] [Related]
11. Oridonin synergizes with Nutlin-3 in osteosarcoma cells by modulating the levels of multiple Bcl-2 family proteins.
Wang XH; Zhang SF; Bao JT; Liu FY
Tumour Biol; 2017 Jun; 39(6):1010428317701638. PubMed ID: 28618955
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations.
Canpolat C; Pearson P; Robertson R; Jaffe N
Med Pediatr Oncol; 1996 Jan; 26(1):36-47. PubMed ID: 7494510
[TBL] [Abstract][Full Text] [Related]
13. Marginal excision for osteosarcoma with caffeine assisted chemotherapy.
Tsuchiya H; Tomita K; Mori Y; Asada N; Yamamoto N
Clin Orthop Relat Res; 1999 Jan; (358):27-35. PubMed ID: 9973973
[TBL] [Abstract][Full Text] [Related]
14. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity.
Bacci G; Ferrari S; Tienghi A; Bertoni F; Mercuri M; Longhi A; Fiorentini G; Forni C; Bacchini P; Rimondini S; De Giorgi U; Picci P
Eur J Surg Oncol; 2001 Feb; 27(1):98-104. PubMed ID: 11237499
[TBL] [Abstract][Full Text] [Related]
15. The effect of intra-arterial versus intravenous cisplatinum in the neoadjuvant treatment of osteosarcoma of the limbs: the experience at the Rizzoli Institute.
Bacci G; Ferrari S; Forni C; Mercuri M; Picci P; Bertoni F; Capanna R; Manfrini M; Donati D; Brach Del Prever A; Baldini N
Chir Organi Mov; 1996; 81(4):369-82. PubMed ID: 9147928
[TBL] [Abstract][Full Text] [Related]
16. [Drug delivery of CPC/cisplatin complex in vitro and its ability to repair bone defect and eliminate tumor in vivo].
Liu Y; Liu M; Ren P
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 34(10):991-7. PubMed ID: 19893250
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of protein phosphatase 2A with the small molecule LB100 overcomes cell cycle arrest in osteosarcoma after cisplatin treatment.
Zhang C; Hong CS; Hu X; Yang C; Wang H; Zhu D; Moon S; Dmitriev P; Lu J; Chiang J; Zhuang Z; Zhou Y
Cell Cycle; 2015; 14(13):2100-8. PubMed ID: 25942376
[TBL] [Abstract][Full Text] [Related]
18. Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma.
Jaffe N; Robertson R; Ayala A; Wallace S; Chuang V; Anzai T; Cangir A; Wang YM; Chen T
J Clin Oncol; 1985 Aug; 3(8):1101-4. PubMed ID: 3874932
[TBL] [Abstract][Full Text] [Related]
19. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
20. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate.
Gobin B; Battaglia S; Lanel R; Chesneau J; Amiaud J; Rédini F; Ory B; Heymann D
Cancer Lett; 2014 Mar; 344(2):291-8. PubMed ID: 24333720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
